FDA Sets Clock for SYMVESS Patent Extension Review
Published Date: 2/19/2026
Notice
Summary
The FDA has set the official review period for SYMVESS, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind SYMVESS and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until April 20 or August 18, 2026, to speak up—potentially impacting patent length and market exclusivity.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA sets SYMVESS review period
If you are the patent holder (Humacyte Global, Inc.), FDA has determined the regulatory review period for SYMVESS is 3,069 days total: 2,694 days in the testing phase and 375 days in the approval phase. FDA lists the key dates as an IND effective July 27, 2016, a BLA submission on December 11, 2023, and approval on December 19, 2024; the applicant requests 1,572 days of patent term extension and the FDA determination establishes the product's maximum potential extension length before USPTO applies statutory limits.
Deadlines to challenge SYMVESS dates
Anyone who thinks the dates are wrong may ask FDA for a redetermination by April 20, 2026, and anyone may petition FDA about whether the applicant acted with due diligence by August 18, 2026. Petitions must follow FDA rules (21 CFR 60.24 and 21 CFR 60.30) and be filed electronically or by written submission as described in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06379 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KRESLADI (marnetegragene autotemcel)
The FDA just gave Rocket Pharmaceuticals a special priority review voucher for their rare pediatric disease treatment, KRESLADI, approved on March 26, 2026. This voucher speeds up future FDA reviews, helping get important medicines to kids with rare diseases faster. It’s a big win for patients, the company, and anyone cheering for quicker cures!
2026-06314 — Determination That INAPSINE (Droperidol) Injection, 2.5 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that INAPSINE (droperidol) injection wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep being approved and sold as long as they follow the rules. Patients and healthcare providers can keep trusting this medicine without worry, and drug makers can continue their work without delays or extra costs.
2026-06294 — Consideration of Acceptable Market Name Change for Certain Rockfish (Sebastes spp.); Request for Information
The FDA wants to hear from fishermen, seafood sellers, and fish lovers about possibly changing the official market names for certain rockfish species. This update aims to make fish labels clearer and safer for everyone, with comments open until May 1, 2026. If the name changes happen, it could affect how these fish are sold and marketed, so your input matters!
2026-06316 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; YUVIWEL (navepegritide)
The FDA just gave Ascendis Pharma a special priority review voucher for their rare pediatric disease drug, YUVIWEL, which helps kids with achondroplasia grow taller. This voucher speeds up future drug reviews and can be a valuable asset, saving time and potentially money. Approved on February 27, 2026, this move highlights the FDA’s commitment to fast-tracking treatments for rare childhood conditions.
2026-06187 — Notice of Decision on a Hearing Request Regarding a Proposal To Refuse To Approve a New Drug Application for TRADIPITANT Capsules
The FDA has decided not to approve Vanda Pharmaceuticals’ new drug, TRADIPITANT capsules, meant to treat symptoms of gastroparesis. Vanda asked for a hearing to challenge this, but the FDA denied it. This means patients and doctors will have to wait longer for this treatment, and Vanda faces delays and extra costs as they figure out their next move.
2026-05913 — Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications; Correction
The FDA fixed a mistake about pulling approvals for 72 generic drug applications. One drug, a valproic acid capsule from Upsher-Smith Laboratories, won’t lose its approval because the company asked to keep it. This means the drug stays available, and the change took effect before October 23, 2025.
Previous / Next Documents
Previous: 2026-03311 — Agency Information Collection Activities; Proposed Collection; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA wants your thoughts on how they collect info about safely processing and importing fish and seafood. This affects businesses that handle fish products, aiming to keep seafood safe and clean. You’ve got until April 20, 2026, to share your comments—no fees, just your voice helping shape safer seafood rules!
Next: 2026-03313 — Agency Information Collection Request. 60-Day Public Comment Request
The Department of Health and Human Services’ Office of Minority Health wants your thoughts on keeping their Think Cultural Health info collection going—no changes, just a renewal. This helps health pros sign up for courses and earn credits to better serve diverse communities. You’ve got until April 21, 2026, to share your comments, and there’s no new cost involved.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in